2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123463
    CHF-1255 146728-52-1 98%
    CHF-1255 is a new aminotetralin. CHF-1255 can be used in the research of heart failure.
    CHF-1255
  • HY-123563
    Metazosin 95549-92-1 98%
    Metazosin (Kenosin) is a potent α1 adrenoceptor blocker. Metazosin is an antihypertensive agent lowering blood pressure.
    Metazosin
  • HY-123569
    ISQ-1 hydrochloride 405165-77-7 98%
    ISQ-1 hydrochloride is an isoquinolinone (IKur) blocker with potential atrial arrhythmic activity. ISQ-1 exhibits cardiac electrophysiological characteristics similar to another structurally distinct IKur blocker previously reported from our laboratory.
    ISQ-1 hydrochloride
  • HY-123613
    AGN192093 159359-95-2 98%
    AGN192093 is a TP agonist (EC50 = 1.3 nM). AGN192093 exhibits potent and selective thromboxane analog activity in rat blood vessels.
    AGN192093
  • HY-123657
    RXP 407 237770-41-1 98%
    RXP 407 is a potent and selective Angiotensin-converting Enzyme (ACE) inhibitor with a Ki of 12nM.
    RXP 407
  • HY-123659
    KR-33028 861218-37-3 98%
    KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke.
    KR-33028
  • HY-123666
    Bay-02752 78991-74-9 98%
    Bay-02752 (Bay o 2752) is a lipid-lowering agent. Bay-02752 inhibits acyl-CoA activity in liver microsomes (IC50 = 0.95 μg/mL). Bay-02752 inhibits intestinal cholesterol absorption in rats. Bay-02752 inhibits gallstone formation in hamsters.
    Bay-02752
  • HY-123679
    FR168888 168620-46-0 98%
    FR168888 is an inhibitor of Na+/H+ exchange with a Ki value of 6.4 nM.
    FR168888
  • HY-123721
    Tiracizine hydrochloride 78816-67-8 98%
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease.
    Tiracizine hydrochloride
  • HY-123793
    MK-1832 935868-50-1 98%
    MK-1832 (Compound 32) is a selective Kv1.5 inhibitor (IC50 = 86 nM). MK-1832 can be used in atrial fibrillation research.
    MK-1832
  • HY-123799
    SB-699393 502638-39-3 98%
    B-699393 (Compound 17) is a BRAF inhibitor (Kd = 7.2 nM) that can cross the blood-brain barrier. SB-699393 can be used for research on stroke.
    SB-699393
  • HY-123803
    PF-06807656 2213468-04-1 98%
    PF-06807656 is a selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor. PF-06807656 has an IC50 of 61 nM against hROMK in patch-clamp assays. PF-06807656 exhibits high selectivity for inhibiting rat ROMK and is insensitive to N171D pore mutations. PF-06807656 may be used in cardiovascular disease research.
    PF-06807656
  • HY-123864
    SC-68448 188804-07-1 98%
    SC-68448 (S 448) is a selective αvβ3 antagonist (IC50 = 1 nM). SC-68448 inhibits αvβ3-mediated endothelial cell proliferation. SC-68448 reduces the total level of αvβ6 in NHBE cells. SC-68448 inhibits angiogenesis in a rat corneal neoplasia model. SC-68448 inhibits tumor growth and completely prevents the development of hypercalcemia in a rat Ledich cell tumor model. SC-68448 can be used in research on cardiovascular and cerebrovascular diseases such as hypercalcemia and cancers such as testicular interstitial cell tumors.
    SC-68448
  • HY-124044
    ML 086 1177148-36-5 98%
    ML 086 is a highly selective PHOSPHO1 phosphatase inhibitor (IC50=0.14 μM). ML 086 is promising for research of hereditary vascular calcification disorders (e.g., generalized arterial calcification of infancy) and spinal ligament ossification.
    ML 086
  • HY-124104
    Aldicarb sulfoxide 1646-87-3 98%
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish.
    Aldicarb sulfoxide
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124133
    JNJ-42905343 1238689-36-5 98%
    JNJ-42905343 is an orally active and highly selective prolyl hydroxylase (PHD1/2/3) inhibitor. JNJ-42905343 is promising for research of functional iron deficiency (FID) and anemia of chronic disease (ACD).
    JNJ-42905343
  • HY-124150
    BM567 284464-77-3 98%
    BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively.
    BM567
  • HY-124153
    GNE-431 1433820-83-7 98%
    GNE-431 is a potent, selective and noncovalent “pan-BTK” inhibitor against C481R, T474I and T474Ms mutants. GNE-431 shows potency against wild-type BTK (IC50= 3.2 nM) and potency against C481S mutant (IC50= 2.5 nM). GNE-431 is proming for rasearch of haematological disorders and autoimmune diseases.
    GNE-431
  • HY-124176
    L-6355 85642-08-6 98%
    L-6355 is an Amiodarone (HY-14187) related compound, which inhibits Ca2+/calmodulin activated cyclic nucleotide phosphodiesterase with an IC50 value of 0.65 μM. L-6355 is promising for research of antiarrhythmic and antianginal agent.
    L-6355
Cat. No. Product Name / Synonyms Application Reactivity